Answers are grounded in this paper and cite their sources.
Background and Hypothesis Alport syndrome (AS) is an inherited glomerular disease that often presents with non-specific clinical and histological features overlapping with other forms of chronic kidney disease (CKD). Consequently, AS may remain unrecognised or misclassified, particularly where genetic testing is unavailable and biopsy is delayed or infeasible. We hypothesised that a non-invasive urinary peptide signature can distinguish AS from other CKD aetiologies, patients with diabetes and healthy individuals. Methods In this multicentre study, we included 165 adults with genetically confirmed AS. Comparator groups comprised patients with non-Alport CKD, diabetes and healthy individuals, matched to the AS cohort by age, sex and estimated glomerular filtration rate (eGFR). Urinary peptide profiles were generated by capillary electrophoresis–mass spectrometry. Group differences in peptide abundance were analysed, and a supervised multipeptide classifier specific for AS was constructed and evaluated in matched test cohorts and in two external validation cohorts: 145 patients with IgA nephropathy (IgAN) and 15 further patients with AS. Results We identified 419 urinary peptides that differed between AS and comparator groups, of which 178 were incorporated into the AS-specific classifier Alport178. In matched test cohorts, Alport178 achieved an AUC of 0.999 (95% CI 0.997–1.00), with 100% sensitivity for AS and high specificity in CKD, diabetic and healthy control groups. In external validation cohorts, the classifier identified most AS cases and classified the majority of IgAN patients as non-Alport. The most informative peptides were predominantly collagen alpha chain fragments. Conclusion A urinary peptidomic classifier specific for AS enables differentiation of AS from other CKD entities, patients with diabetes, healthy individuals and IgAN. This non-invasive approach may facilitate earlier recognition of AS, reduce the need for invasive diagnostic procedures and prioritise patients for confirmatory genetic testing and targeted management.
No takes yet. Share an insight, caveat, or question.
Byrska et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: